Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Translational Research in Cancer Drug Development

Indonesian Journal of Cancer Chemoprevention · Vol. 2 No. 2 (2011) · hlm. 198–211

DOI
10.14499/indonesianjcanchemoprev2iss2pp198-211
ISSN
2355-8989, 2088-0197
Terbit
2011-06-28
Penerbit
Indonesian Society for Cancer Chemoprevention
Bahasa
eng

Abstrak

The development of cancer treatment were initiated by the existence of human’s effort to treat by applying certain materials which is mostly part(s) or extracts of plants, which are now adapted as traditional herbal medicine. The discovery of new drugs was based on intuition and empirical evidence. Thus, high luck factor was involved in a successful treatment with unguaranteed reproducibility. One example of drug being developed through conventional drug development is Taxol. Taxol is an extremely complex natural product and requires a bunch of hard work with high level of serendipity to be discovered as antitumor agent. Recently, rapid development in human biology and technology allow a change in drug discovery strategy by minimizing the luck factor. Targeted therapy has been a very promising strategy of drug development research, especially in cancer treatment. Although cancer has been known as a disease with very complex cellular and histo-pathophysiology, the abundance of studies on proteins, such as receptors and hormones, as the hallmarks of cancer allows us to explore carcinogenesis suppression further based on molecular targeted therapy. Kinases, one type of protein involved in signal transduction regulating cell growth and differentiation, could be the proteins that are proposed to be inhibited in suppressing tumor growth. An interesting example of the drug being discovered based on molecular modeling is the discovery of lapatinib as anti- cancer with specific target on HER-2 and EGFR to overcome the resistance of cancer to Herceptin caused by elevated level of EGFR expression.Keywords: targeted therapy, cancer, translational drug development

Jaringan kolaborasi para penulis

40 penulis · 144 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • IPB University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Ratna Asmah SusidartiAfiliasi tidak diketahui20
Riris Istighfari JenieAfiliasi tidak diketahui17
Muthi’ IkawatiAfiliasi tidak diketahui13
Rohmad Yudi UtomoAfiliasi tidak diketahui12
Dyaningtyas Dewi Pamungkas PutriAfiliasi tidak diketahui10
Sari HaryantiAfiliasi tidak diketahui5
Dhania NovitasariAfiliasi tidak diketahui5
Desty Restia RahmawatiAfiliasi tidak diketahui5
Retno MurwantiAfiliasi tidak diketahui4
Faaza Aulia RahmanAfiliasi tidak diketahui4
Larasati LarasatiIPB University4
Lailatul QodriaAfiliasi tidak diketahui4
Gergorius Gena MaranAfiliasi tidak diketahui4
Sri HandayaniUniversity of Brawijaya3
Ummi Maryam ZulfinAfiliasi tidak diketahui3
Erlina RivantiAfiliasi tidak diketahui3
Sendy JunediAfiliasi tidak diketahui3
Sofa FaridaAfiliasi tidak diketahui3
Indri KusharyantiAfiliasi tidak diketahui3
Nanda Resa PratamaAfiliasi tidak diketahui3
Yurista GilangAfiliasi tidak diketahui3
Nindya Budiana PutriAfiliasi tidak diketahui3
Herwandhani PutriAfiliasi tidak diketahui3
Ika NurzijahAfiliasi tidak diketahui3
Masashi KawaichiAfiliasi tidak diketahui2
Nunuk Aries NurulitaAfiliasi tidak diketahui2
Suwijiyo PramonoAfiliasi tidak diketahui2
Zalinar UdinAfiliasi tidak diketahui2
Yogi ErtantoAfiliasi tidak diketahui2
Aulia Nur SeptianiAfiliasi tidak diketahui2
Beni LestariAfiliasi tidak diketahui2
Asri Mega PutriAfiliasi tidak diketahui2
Hilyatul FadliyahAfiliasi tidak diketahui2
Yonika Arum LarasatiAfiliasi tidak diketahui2
Raditya Prima IstiajiAfiliasi tidak diketahui2
Ni Putu Linda LaksmianiAfiliasi tidak diketahui2
Astrid Ayu MarutiAfiliasi tidak diketahui2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ijcc.chemoprev.org/index.php/ijcc/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Translational Research in Cancer Drug Development</dc:title>
	<dc:creator>Meiyanto, Edy</dc:creator>
	<dc:creator>Hermawan, Adam</dc:creator>
	<dc:creator>Anindyajati, Anindyajati</dc:creator>
	<dc:description xml:lang="en-US">The development of cancer treatment were initiated by the existence of human’s effort to treat by applying certain materials which is mostly part(s) or extracts of plants, which are now adapted as traditional herbal medicine. The discovery of new drugs was based on intuition and empirical evidence. Thus, high luck factor was involved in a successful treatment with unguaranteed reproducibility. One example of drug being developed through conventional drug development is Taxol. Taxol is an extremely complex natural product and requires a bunch of hard work with high level of serendipity to be discovered as antitumor agent. Recently, rapid development in human biology and technology allow a change in drug discovery strategy by minimizing the luck factor. Targeted therapy has been a very promising strategy of drug development research, especially in cancer treatment. Although cancer has been known as a disease with very complex cellular and histo-pathophysiology, the abundance of studies on proteins, such as receptors and hormones, as the hallmarks of cancer allows us to explore carcinogenesis suppression further based on molecular targeted therapy. Kinases, one type of protein involved in signal transduction regulating cell growth and differentiation, could be the proteins that are proposed to be inhibited in suppressing tumor growth. An interesting example of the drug being discovered based on molecular modeling is the discovery of lapatinib as anti- cancer with specific target on HER-2 and EGFR to overcome the resistance of cancer to Herceptin caused by elevated level of EGFR expression.Keywords : targeted therapy, cancer, translational drug development</dc:description>
	<dc:publisher xml:lang="en-US">Indonesian Society for Cancer Chemoprevention</dc:publisher>
	<dc:contributor xml:lang="en-US"></dc:contributor>
	<dc:date>2011-06-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijcc.chemoprev.org/index.php/ijcc/article/view/32</dc:identifier>
	<dc:identifier>10.14499/indonesianjcanchemoprev2iss2pp198-211</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Cancer Chemoprevention; Vol 2, No 2 (2011); 198-211</dc:source>
	<dc:source>2355-8989</dc:source>
	<dc:source>2088-0197</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/view/32/33</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2017 Indonesian Journal of Cancer Chemoprevention</dc:rights>
</oai_dc:dc>